MOUNTAIN VIEW, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the first quarter of 2024 after market close on Wednesday, May 8, 2024. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m.... Read More

MOUNTAIN VIEW, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will present at the Needham 23rd Annual Healthcare Conference, taking place virtually from April 8-11. Joel Becker, NeuroPace’s Chief Executive Officer, will provide a corporate presentation on Monday, April 8 at 3:45pm ET, and... Read More

Revenue increased to $18.0 million in Q4 2023, a 41% increase over Q4 2022 Revenue increased to $65.4 million in 2023, a 44% increase over 2022 Provides full-year 2024 revenue guidance of between $73-$77 million Management scheduled to host a conference call today at 4:30 p.m. ET MOUNTAIN VIEW, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the... Read More

MOUNTAIN VIEW, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the fourth quarter and full year 2023 after market close on Tuesday, March 5, 2024. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m.... Read More

Preliminary unaudited revenue expected to be between $17.5 million and $18.0 million for Q4 2023 and between $64.9 million and $65.4 million for full year 2023 Company begins 2024 with cash balance of $66.5 million Announces completion of patient implant milestone in the NAUTILUS trial Completed initial milestones in first strategic data collaboration, using proprietary biomarker monitoring and data analysis capabilities to... Read More

NAUTILUS is the first and only pivotal clinical study to evaluate neuromodulation therapy for treating drug refractory idiopathic generalized epilepsy Neuromodulation therapy is not currently indicated for patients with drug refractory generalized epilepsy If successful, NeuroPace’s RNS System would represent the first neuromodulation indication in idiopathic generalized epilepsy MOUNTAIN VIEW, Calif., Dec. 21, 2023 (GLOBE... Read More

MOUNTAIN VIEW, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 42 nd Annual J.P. Morgan Healthcare Conference at 7:30am PT (10:30am ET) on Thursday, January 10, 2024, in San Francisco, CA as well as host investor meetings prior to... Read More

First of its kind, multi-year collaboration leverages RNS System’s data to track responses of implanted RNS System patients enrolled in a biotechnology company’s clinical trial In strategic data collaboration, clinical-stage biotechnology company to pay NeuroPace up to $3.7 million over two years to gain non-exclusive access to NeuroPace’s proprietary biomarker monitoring and data analysis capabilities for trial patients... Read More

MOUNTAIN VIEW, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company will have a substantial presence at the 77th American Epilepsy Society Annual Meeting (AES 2023), to be held in Orlando, Florida and virtually from December 1-5, 2023. “The Society’s annual meeting... Read More

MOUNTAIN VIEW, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced will present at the Piper Sandler 35 th Annual Healthcare Conference, taking place November 28-30 in New York, NY. Joel Becker, NeuroPace’s Chief Executive Officer, will provide a corporate presentation on Tuesday,... Read More

Third quarter 2023 revenue of $16.4 million, an increase of 47% year-over-year Full-year revenue guidance increased to $62.5-$63.5 million, up from $59-$61 million Cash burn reduced to $2.2 million in the third quarter of 2023, relative to $4 million in the second quarter of 2023 MOUNTAIN VIEW, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on... Read More

Upgraded nSight Platform Improves Clinicians’ Ability to Track, Review and Evaluate Patient Data ‘Simple Set Programming’ Enables Complete Programming Set Transfer Directly to RNS Tablet FDA Approval of Smaller, Portable and Simpler Tablet Remote Monitor with Wireless Connectivity MOUNTAIN VIEW, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on... Read More

MOUNTAIN VIEW, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced participation in a fireside chat discussion at the upcoming 2023 Cantor Fitzgerald Global Healthcare Conference on Thursday, September 28, 2023, at 1:15 p.m. ET in New York, New York. A live webcast of the Cantor... Read More

Wells Fargo 2023 Healthcare Conference Morgan Stanley 21 st Annual Global Healthcare Conference Lake Street Capital Markets 7 th Annual Best Ideas Growth Conference MOUNTAIN VIEW, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced its participation in the following upcoming... Read More

Second quarter 2023 revenue of $16.5 million increased 62% year-over-year Full-year revenue guidance increased to $59-$61 million, up from $52-54 million Cash burn reduced to $4 million in the second quarter of 2023, relative to $9.8 million in the first quarter of 2023 MOUNTAIN VIEW, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming... Read More

MOUNTAIN VIEW, Calif., July 19, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced that it granted to Joel Becker, NeuroPace’s recently-appointed Chief Executive Officer and director, an option to purchase 380,424 shares of NeuroPace’s common stock at an exercise price of $4.39 under its 2023... Read More

MOUNTAIN VIEW, Calif., July 18, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the second quarter of 2023 after market close on Tuesday August 8, 2023. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time... Read More

NeuroPace Appoints Joel Becker as President & CEO Becker Brings a Track Record of Strong Commercial Execution and Deep Medical Device Operating Expertise Mike Favet to leave Company after four years as President, CEO and Board Member and will continue to advise through transition MOUNTAIN VIEW, Calif., June 28, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on... Read More

MOUNTAIN VIEW, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc . (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced the appointment of Ms. Kelley Nicholas as Vice President of Sales effective May 22, 2023. “I am thrilled to have Kelley Nicholas join NeuroPace as Vice President of Sales,” said Mike Favet, Chief Executive Officer... Read More

First quarter 2023 revenue increased 27% year-over-year to $14.5 million Full-year revenue guidance updated on strength of first quarter performance. Now expected to be $52-$54 million, up from $50-$52 million MOUNTAIN VIEW, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today reported... Read More

MOUNTAIN VIEW, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the first quarter of 2023 after market close on Thursday, May 4, 2023. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time... Read More

MOUNTAIN VIEW, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will be participating in the upcoming 22 nd Annual Needham Virtual Healthcare Conference. Management is scheduled to present on Monday, April 17 th , 2023 at 7:15 a.m. Pacific Time / 10:15 a.m. Eastern Time. A... Read More

MOUNTAIN VIEW, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the fourth quarter and full-year ended December 31, 2022. Recent Highlights Achieved total revenue of $12.8 million for the fourth quarter of 2022, representing a 16% increase over the fourth... Read More

MOUNTAIN VIEW, Calif., Feb. 10, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the fourth quarter and full year of 2022 after market close on Thursday, March 2, 2023. The company’s management will webcast a corresponding conference call beginning at 1:30... Read More

MOUNTAIN VIEW, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced preliminary, unaudited revenue results for the fourth quarter and full-year ended December 31, 2022 and the appointment of Dr. Uri Geiger to its Board of Directors. Preliminary Unaudited Fourth Quarter 2022 Total... Read More

MOUNTAIN VIEW, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will be participating in the upcoming 41 st Annual J.P. Morgan Healthcare Conference in San Francisco, California. Management is scheduled to present on Thursday, January 12 t h , 2023 at 9:00 a.m. Pacific Time /... Read More